Provided project management support and supervised CRO/CMO activities in relation to the synthesis of API, formulation of drug product, and the pre-clinical development of the CG’806 small molecule asset that was being developed for the treatment of hematologic malignancies.

Supported a Phase 1b study examining the safety and activity of APTO-253 in patients with advanced hematologic malignancies through maintenance of study timelines, supervising CRO monitoring activities, study start-up documentation generation, attainment of IRB approvals, coordination of cross functional meetings, and budgeting activities.

Supported two Phase 1b/2 studies examining the safety and activity of oprozomib in patients with multiple myeloma and Waldenström macroglobulinemia.

Designed pre-clinical studies and lead teams to conduct laboratory assays to determine the efficacy, tolerably, and expression level of viral vectors created for the therapeutic treatment of cancer and worked with the Clinical Operations group to support the Imvamune vaccine program.

Assisted in the discovery and optimization of new and innovative assays to screen and evaluate large molecule biologics designed as therapeutic candidates in murine models of human disease.

Worked as part of a collaborative team that characterized the pharmacological properties of small molecule compounds intended for therapeutic use in oncology, metabolism, and inflammatory diseases.